Glycosaminoglycans modulate RANKL‐induced osteoclastogenesis

No abstract is available for this paper.

• Publication year

  2010

• Venue

  Journal of Cellular Biochemistry

• Publication date

  2010-04-15

• Fields of study

  Biology, Medicine, Chemistry

• Identifiers
  DOI 10.1002/jcb.22506PMID 20135643PMCID PMC3095103
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• RANKL-mediated osteoclast formation from murine RAW 264.7 cells.

  2012cited by this paper
• The heparan sulfate proteoglycan (HSPG) glypican‐3 mediates commitment of MC3T3‐E1 cells toward osteogenesis

  2009cited by this paper
• Local communication on and within bone controls bone remodeling.

  2009cited by this paper
• De‐sulfation of MG‐63 cell glycosaminoglycans delays in vitro osteogenesis, up‐regulates cholesterol synthesis and disrupts cell cycle and the actin cytoskeleton

  2009cited by this paper
• The osteogenic transcription factor Runx2 regulates components of the fibroblast growth factor/proteoglycan signaling axis in osteoblasts

  2009cited by this paper
• Heparin inhibits osteoclastic differentiation and function

  2008influential reference
• Bone remodeling: Multiple cellular interactions required for coupling of bone formation and resorption.

  2008cited by this paper
• The Structure of Glycosaminoglycans and their Interactions with Proteins

  2008cited by this paper
• Effects of neridronic acid on osteoclasts derived by physiological dual-cell cultures.

  2007cited by this paper
• Temporal and functional changes in glycosaminoglycan expression during osteogenesis

  2007cited by this paper
• Proteoglycans: key partners in bone cell biology

  2007cited by this paper
• Poly(3-hydroxybutyrate-co-3-hydroxyvalerate) composite biomaterials for bone tissue regeneration: in vitro performance assessed by osteoblast proliferation, osteoclast adhesion and resorption, and macrophage proinflammatory response.

  2007cited by this paper
• Heparan sulfate regulates the anabolic activity of MC3T3‐E1 preosteoblast cells by induction of Runx2

  2007cited by this paper
• Heparin enhances osteoclastic bone resorption by inhibiting osteoprotegerin activity.

  2007cited by this paper
• Dermatan sulfate inhibits osteoclast formation by binding to receptor activator of NF-κB ligand

  2007influential reference
• Dermatan sulfate inhibits osteoclast formation by binding to receptor activator of NF-kappa B ligand.

  2007influential reference
• Characterization of osteoprotegerin binding to glycosaminoglycans by surface plasmon resonance: role in the interactions with receptor activator of nuclear factor kappaB ligand (RANKL) and RANK.

  2006cited by this paper
• Heparan sulfate regulation of progenitor cell fate

  2006cited by this paper
• Bone‐specific heparan sulfates induce osteoblast growth arrest and downregulation of retinoblastoma protein

  2006cited by this paper
• Sulfated glycosaminoglycans mediate the effects of FGF2 on the osteogenic potential of rat calvarial osteoprogenitor cells

  2006cited by this paper
• Characterization of osteoprotegerin binding to glycosaminoglycans by surface plasmon resonance: Role in the interactions with receptor activator of nuclear factor κB ligand (RANKL) and RANK

  2006cited by this paper
• Coordinated fibroblast growth factor and heparan sulfate regulation of osteogenesis.

  2006cited by this paper
• Mechanisms Involved in Enhancement of Osteoclast Formation and Function by Low Molecular Weight Hyaluronic Acid*

  2005cited by this paper
• Localization of osteoprotegerin, tumor necrosis factor-related apoptosis-inducing ligand, and receptor activator of nuclear factor-kappaB ligand in Mönckeberg's sclerosis and atherosclerosis.

  2004cited by this paper
• Role of RANK ligand in mediating increased bone resorption in early postmenopausal women.

  2003cited by this paper
• RANKL-mediated osteoclast formation from murine RAW 264.7 cells.

  2003cited by this paper
• Phenotypic Characterization of Early Onset Paget's Disease of Bone Caused by a 27‐bp Duplication in the TNFRSF11A Gene

  2003cited by this paper
• Sulfated Polysaccharides Enhance the Biological Activities of Bone Morphogenetic Proteins*

  2003cited by this paper
• Expansile Skeletal Hyperphosphatasia Is Caused by a 15‐Base Pair Tandem Duplication in TNFRSF11A Encoding RANK and Is Allelic to Familial Expansile Osteolysis

  2002cited by this paper
• The phosphatidylinositol 3-kinase, p38, and extracellular signal-regulated kinase pathways are involved in osteoclast differentiation.

  2002cited by this paper
• Changes in osteoprotegerin and markers of bone metabolism during glucocorticoid treatment in patients with chronic glomerulonephritis.

  2002cited by this paper
• Osteoprotegerin deficiency and juvenile Paget's disease.

  2002cited by this paper
• Regulatory mechanisms of osteoblast and osteoclast differentiation.

  2002cited by this paper
• Osteoprotegerin deficiency and juvenile Paget's disease.

  2002cited by this paper
• U0126 and PD98059, Specific Inhibitors of MEK, Accelerate Differentiation of RAW264.7 Cells into Osteoclast-like Cells*

  2002influential reference
• Induction and activation of the transcription factor NFATc1 (NFAT2) integrate RANKL signaling in terminal differentiation of osteoclasts.

  2002cited by this paper
• Multiple myeloma disrupts the TRANCE/ osteoprotegerin cytokine axis to trigger bone destruction and promote tumor progression

  2001cited by this paper
• Dynamics of Bone and Cartilage Metabolism.

  2001cited by this paper
• Immunolocalization of keratan sulfate proteoglycan in rat calvaria.

  2001cited by this paper
• Minireview: the OPG/RANKL/RANK system.

  2001cited by this paper
• Mutations in TNFRSF11A, affecting the signal peptide of RANK, cause familial expansile osteolysis

  2000cited by this paper
• Involvement of p38 Mitogen-activated Protein Kinase Signaling Pathway in Osteoclastogenesis Mediated by Receptor Activator of NF-κB Ligand (RANKL)*

  2000cited by this paper
• Involvement of p38 mitogen-activated protein kinase signaling pathway in osteoclastogenesis mediated by receptor activator of NF-kappa B ligand (RANKL).

  2000cited by this paper
• Specificities of heparan sulphate proteoglycans in developmental processes

  2000cited by this paper
• Diverse roles of the tumor necrosis factor family member TRANCE in skeletal physiology revealed by TRANCE deficiency and partial rescue by a lymphocyte-expressed TRANCE transgene.

  2000cited by this paper
• RANK is essential for osteoclast and lymph node development.

  1999cited by this paper
• Tumor necrosis factor receptor family member RANK mediates osteoclast differentiation and activation induced by osteoprotegerin ligand.

  1999cited by this paper
• The Ligand for Osteoprotegerin (OPGL) Directly Activates Mature Osteoclasts

  1999cited by this paper
• A new member of tumor necrosis factor ligand family, ODF/OPGL/TRANCE/RANKL, regulates osteoclast differentiation and function.

  1999cited by this paper
• Cell biology of the osteoclast.

  1999cited by this paper
• Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation.

  1998cited by this paper
• osteoprotegerin-deficient mice develop early onset osteoporosis and arterial calcification.

  1998cited by this paper
• Severe osteoporosis in mice lacking osteoclastogenesis inhibitory factor/osteoprotegerin.

  1998cited by this paper
• Matrix proteoglycans: from molecular design to cellular function.

  1998cited by this paper
• TRANCE Is Necessary and Sufficient for Osteoblast-mediated Activation of Bone Resorption in Osteoclasts

  1998cited by this paper
• Modulation of osteoclast differentiation.

  1992cited by this paper
• Intermittent cyclical etidronate treatment of postmenopausal osteoporosis.

  1990cited by this paper
• Proteoglycans synthesized by cultured mouse osteoblasts.

  1987cited by this paper
• Isolation of three species of proteoglycan synthesized by cloned bone cells.

  1983cited by this paper
• [Mast cells, basophils and heparin liberation].

  1963cited by this paper

• C4ST-1 Overexpression Suppresses Osteoblast Differentiation via a Wnt/β-Catenin-p53 Axis.

  2026cites this paper
• Mechanisms responsible for the ability of enoxaparin sodium to inhibit inflammatory responses in the immune microenvironment of bone repair: A transcriptomic sequencing study

  2025cites this paper
• CGK733 alleviates ovariectomy-induced bone loss through blocking RANKL-mediated Ca2+ oscillations and NF-κB/MAPK signaling pathways

  2023cites this paper
• Biological role of heparan sulfate in osteogenesis: A review.

  2021cites this paper
• New insights into the role of glycosaminoglycans in the endosteal bone microenvironment

  2021cites this paper
• Octacalcium Phosphate Bone Substitute (Bontree®): From Basic Research to Clinical Case Study

  2021cites this paper
• A biomimetic collagen-bone granule-heparan sulfate combination scaffold for BMP2 delivery.

  2020cites this paper
• Trabecular Bone Deficit and Enhanced Anabolic Response to Re-Ambulation after Disuse in Perlecan-Deficient Skeleton

  2020cites this paper
• Selective regulation of RANKL/RANK/OPG pathway by heparan sulfate through the binding with estrogen receptor β in MC3T3-E1 cells.

  2020cites this paper
• A polycaprolactone-β-tricalcium phosphate-heparan sulphate device for cranioplasty.

  2019cites this paper
• Effect of calcium phosphate heparinization on the in vitro inflammatory response and osteoclastogenesis of human blood precursor cells

  2019cites this paper
• Nanoparticulate mineralized collagen glycosaminoglycan materials directly and indirectly inhibit osteoclastogenesis and osteoclast activation

  2019cites this paper
• Osteoblastic heparan sulfate regulates osteoprotegerin function and bone mass.

  2018cites this paper
• Recombinant Heparin—New Opportunities

  2018cites this paper
• The role of active ingredients nanopowder Stichopus hermanii gel to bone resorption in tension area of orthodontic tooth movement

  2017cites this paper
• Advances in the Use of Stem Cells in Veterinary Medicine: From Basic Research to Clinical Practice

  2016cites this paper
• A Modified Glycosaminoglycan, GM-0111, Inhibits Molecular Signaling Involved in Periodontitis

  2016cites this paper
• N-acetylglucosamine suppresses osteoclastogenesis in part through the promotion of O-GlcNAcylation

  2016cites this paper
• Effect of heparin on the biological properties and molecular signature of human mesenchymal stem cells.

  2016cites this paper
• Whole body vibration improves osseointegration by up-regulating osteoblastic activity but down-regulating osteoblast-mediated osteoclastogenesis via ERK1/2 pathway.

  2015cites this paper
• Osteoblast-released Matrix Vesicles, Regulation of Activity and Composition by Sulfated and Non-sulfated Glycosaminoglycans*

  2015influential citation
• Glycosaminoglycan Mimetic Associated to Human Mesenchymal Stem Cell-Based Scaffolds Inhibit Ectopic Bone Formation, but Induce Angiogenesis In Vivo

  2013cites this paper
• Affinity-selected heparan sulfate for bone repair.

  2013cites this paper
• Proteoglycans and osteolysis.

  2012cites this paper
• Sulfated hyaluronan/collagen I matrices enhance the osteogenic differentiation of human mesenchymal stromal cells in vitro even in the absence of dexamethasone.

  2012cites this paper
• Regenerative potential of glycosaminoglycans for skin and bone

  2011cites this paper
• Heparan sulfate-based treatments for regenerative medicine.

  2011cites this paper
• Mélanges de glycosaminoglycanes

  2010cites this paper